NLS Pharmaceutics AG (NLSP) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Price to Book (PBV) Ratio Undervalued price-to-book. NLSP stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) NLSP equity is higher than it's debt.
Return of Equity NLSP has GREAT return of equity (257.32%).
Return of Invested Capital Good ROIC. NLSP is thought to be creating value.

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth NLSP has never had growing revenue.
Net Income Growth NLSP has never had growing net income.
Net Income NLSP never has positive net income for 2 years.
Dividend Yield NLSP has low dividend yield (0%).
Return of Assets NLSP has low return of asset (-257.38%).
Revenue NLSP never has positive revenue for 2 years.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-14,975,604 USD

Dividend

Financial Ratios

CEO

CEO Name

Management

About NLS Pharmaceutics AG

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Additional Information

Company name

NLS Pharmaceutics AG

Symbol

NASDAQ:NLSP

Exchange

NASDAQ Capital Market

Industry

Biotechnology

Sector

Healthcare

Address

Alter Postplatz 2
Stans

CH
8058

Website

https://nlspharma.com